Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study of NBM-BMX and Temozolomide in Newly Diagnosed Glioblastoma
NCT07569042Phase 2Recruiting
- Sponsor
- Novelwise Pharmaceutical Corporation
- Start
- Apr 2026
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NBM-BMX in glioblastoma (GBM), sponsored by Novelwise Pharmaceutical Corporation. Started Apr 2026; status: recruiting.
02
Drugs
NBM-BMX
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07569042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07569042.